The purpose of the study is to see whether using indocyanine green during surgery helps the team find and remove more lymph nodes (small glands that are part of the body’s immune system) and whether this changes the surgery in any helpful or harmful way. Some patients will have surgery with the dye and the special light imaging, while others will have the same type of surgery without it. The study includes operations such as nephroureterectomy (removal of a kidney and the tube that carries urine from it) and retroperitoneal lymph node dissection (removal of lymph nodes from the back part of the abdomen).

During the study, the dye is given before or during surgery, and the surgical team then carries out the planned operation and removes tissue as needed. After surgery, the medical team checks for any side effects from the dye and watches for usual surgery-related problems during recovery. The study also looks at how the surgery went overall and how well the dye appeared to help during the procedure.

The study will involve administering patritumab deruxtecan to participants through an intravenous infusion, which means the medication is given directly into a vein. The trial will be conducted in two parts. In the first part, researchers will focus on understanding how safe the treatment is and determining the best dose to use. In the second part, they will look at how well the treatment works in controlling the cancer. Throughout the study, participants will be closely monitored for any side effects and to see how their cancer responds to the treatment.

In addition to patritumab deruxtecan, other medications may be used to help manage symptoms or side effects. These include dexamethasone, which is a type of steroid, and other medications that help prevent nausea and vomiting. The study aims to provide valuable information on the potential benefits and risks of using patritumab deruxtecan in treating these challenging pediatric cancers.

The purpose of the study is to determine the appropriate dose of lutetium Lu 177 edotreotide for children, based on its safety and how it moves through the body. The study will involve giving the treatment to participants and monitoring them to see how their bodies respond. This includes checking for any side effects and measuring how the treatment is absorbed by the body. The study will also look at how effective the treatment is in reducing the size of the tumors.

Participants in the study will receive the treatment through an intravenous infusion, which means it will be given directly into a vein. The study will take place over several cycles, with regular check-ups to monitor the participants’ health and the progress of the treatment. The goal is to find the safest and most effective dose for treating these types of tumors in children. The study is expected to continue for several years to gather enough information to make informed decisions about the treatment’s use in the future.

The study aims to determine if adding tTF-NGR to standard trabectedin treatment helps keep the cancer under control for a longer time. Both medications are given through an intravenous infusion directly into the bloodstream. The experimental drug tTF-NGR is designed to concentrate the chemotherapy medication inside the tumor.

During the study, participants receive treatment for up to 360 days. Some patients will receive only trabectedin, while others will receive both trabectedin and tTF-NGR. Regular medical examinations and imaging tests will be performed to monitor how the cancer responds to the treatment. The study focuses on patients whose tumors show a specific characteristic called CD13 positivity, which is determined through laboratory testing.

The main purpose is to find better treatment options for both newly diagnosed and relapsed rhabdomyosarcoma in children and adults. The study will evaluate different timing and doses of chemotherapy and radiation therapy. Some patients will receive standard treatment while others will receive new combinations of medications.

The trial will last several years, with an estimated completion date in 2030. Throughout the study, researchers will monitor how well the treatments work by measuring survival rates and checking if the cancer returns. They will also track side effects and complications from the treatments.

The purpose of this study is to find the best dose of Crizotinib when used with Temsirolimus and to assess the safety and initial effectiveness of Crizotinib on its own in treating these specific gene-positive tumors. Participants in the study will receive either Crizotinib alone or in combination with Temsirolimus, depending on their specific cancer type and genetic markers. The study will monitor how the body responds to the treatment and any side effects that may occur.

Throughout the study, participants will undergo regular check-ups and tests to track their progress and the impact of the treatment on their cancer. The study aims to gather important information that could help improve treatment options for children with these types of cancers in the future. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment. The study is expected to continue until the end of 2029.

The purpose of the study is to assess the safety and effectiveness of this combination of drugs. The study is divided into two phases. In the first phase, researchers will determine the best dose of ribociclib to use with the other medications. In the second phase, the study will further evaluate how well this combination works in treating neuroblastoma compared to a placebo. Participants will receive the medications either orally or through intravenous infusion, depending on the specific drug.

Throughout the study, participants will be closely monitored for any side effects and to see how their tumors respond to the treatment. The study aims to find the most effective and safe way to use these medications together to help treat these challenging cancers in young patients. The trial is expected to continue until 2029, allowing researchers to gather comprehensive data on the treatment’s impact.

The study combines two types of treatment: a medication called trabectedin (given through an intravenous infusion) and low-dose radiation therapy. Trabectedin is administered as a solution that is prepared from a powder and given through a special tube placed in a vein. The dose used in this study is 1.5 milligrams per square meter of body surface.

The main goal of this research is to determine how well tumors respond to this combination treatment, particularly in areas that receive radiation therapy. Throughout the study, researchers will monitor changes in tumor size, track how long the treatment remains effective, and assess its effects on pain levels and overall well-being. They will also carefully watch for any side effects that may occur during treatment.

Participants in the study will take lenvatinib in the form of a capsule, which is taken by mouth. The study will monitor the response of the tumors to the treatment over a period of time, specifically looking at the changes in the size of the tumors and any side effects experienced by the participants. The study aims to determine the effectiveness of lenvatinib in shrinking the tumors and improving the condition of the patients.

The study will last for several weeks, during which participants will receive regular check-ups and assessments to track their progress. The researchers will use specific criteria to evaluate the response of the tumors to the treatment, ensuring that the results are accurate and reliable. This study is an important step in finding better treatment options for young patients with these challenging types of cancer.

The purpose of the study is to find out which combination of these treatments is safe and effective for young patients with these challenging types of cancer. In the first stage of the study, researchers will determine which of the three chemotherapy regimens is safe to use with Nivolumab. The regimens being tested are: Cyclophosphamide and Vinblastine; Capecitabine alone; and a combination of Cyclophosphamide, Vinblastine, and Capecitabine. In the second stage, the study will focus on the most promising regimen from the first stage, with or without Nivolumab, to see how well it works in preventing the cancer from getting worse.

Participants in the study will receive their treatments either through an intravenous method, which means the medication is given directly into a vein, or orally, which means taking the medication by mouth. The study will monitor the participants over time to assess the safety of the treatments and their effectiveness in controlling the cancer. The study aims to provide valuable information that could lead to better treatment options for children and teenagers facing these difficult cancers.

The study will be conducted in two parts. In the first part, participants with advanced solid tumors will receive the combination of cobolimab and dostarlimab to assess safety and determine the appropriate dosage. In the second part, the study will focus on specific types of cancer, including melanoma and Hodgkin lymphoma, to evaluate the effectiveness of the treatment. Participants will receive the medications through an intravenous infusion, which means the medicine is given directly into a vein.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The trial will help researchers gather important information about the potential benefits and risks of using cobolimab and dostarlimab together in treating these challenging conditions. The study is expected to continue until 2030, providing valuable insights into new treatment options for young patients with difficult-to-treat tumors.